Abstract: An image forming method is provided. The method includes the steps of forming an electrostatic latent image on a photoconductor; developing the electrostatic latent image into a toner image with a toner; transferring the toner image onto a recording medium having a smoothness of 20 s or less; and fixing the toner image on the recording medium. The toner exhibits an adhesion force of 100 gf or more, where the adhesion force is the maximum value of a pull force between a layer of the toner and standard paper determined by a tacking test with a probe temperature of 140° C.

Abstract: A toner includes a base particle; and an external additive covering the base particle. The toner includes a tetrahydrofuran (THF)-insoluble component having a glass transition temperature determined from a DSC curve when heated for the second time of from ?50° C. to 10° C. and an average circularity not greater than 0.98, and satisfies the following relation: Bt?0.025×Ct?1.80 wherein Bt represents a BET specific surface area [m2/g]; and Ct represents a coverage [%] of the external additive covering the base particle.

Abstract: A toner includes a base particle comprising a crystalline polyester resin; and an external additive which is a group of silica particles having a number-average particle diameter of from 0.01 ?m to 0.11 ?m on the surface of the toner. A number ratio of the silica particles having a circularity not less than 0.8 is 20% or more in the total number of the silica particles.

Abstract: The present invention relates to a method for evaluating the activity level of mesenchymal stem cells, and a method for culturing mesenchymal stem cells using the evaluation method in the field of culturing mesenchymal stem cells for regenerative medicine, and further, a method for producing a therapeutic agent for liver dysfunction and a therapeutic agent for liver dysfunction. This method for evaluating mesenchymal stem cell activity according to the present invention comprises an assay step for assaying the amount of adenylate kinase 4 (AK4) in the mesenchymal stem cells; and a determination step for determining the activity level of the mesenchymal stem cells from the assayed amount of adenylate kinase 4.

Abstract: The present invention provides a substituted biaryl compound of general formula (I): wherein, R1, W, R2, and Z are as defined in the claims and the description, or a pharmacologically acceptable salt thereof. The compound according to the present invention has an excellent inhibition effect of pulmonary fibroblast proliferation, and is therefore useful as a therapeutic agent and/or a prophylactic agent for interstitial pneumonia and pulmonary fibrosis.

Abstract: The present invention relates to a method for producing a cell mass structure, which produces a cell mass structure (adhesion pad 4) in which a plurality of cell aggregates 2 arranged inside a culture container 3 accommodating a culture liquid are fused to each other by being cultured. A plurality of pins 16 are erected inside the above-described culture container 3, the above-described cell aggregates 2 are accommodated by the plurality of pins 16 with parts between the plurality of pins 16 and pins 16 as accommodating portions H, and the cell aggregates 2 are cultured in a state of being accommodated in the plurality of adjacent accommodating portions H. It is possible to obtain a required shape and dimension, and the cell mass structure can be obtained without giving damage to cells further.

Abstract: An apparatus 1 for producing a cell mass sheet is structured so as to produce a cell mass sheet 4 in which a plurality of cell masses 2 that have been planarly arranged on a mounting surface 13a in a culture container 3 are fused to each other by being cultured. The apparatus includes guide means G that has a plurality of accommodating portions Ga which can accommodate the cell masses 2 therein, and suction nozzles 8 (supply means) that supply the cell masses 2 into the accommodating portions Ga of the guide means G, which are arranged on the mounting surface 13a; and is structured so that the suction nozzles 8 array the cell masses 2 on the mounting surface 13a, and after that, the guide means G retracts from the above the mounting surface 13a. The apparatus can produce a cell mass sheet that has a constant shape and also a uniform thickness.

Abstract: A toner includes a base particle; and an external additive covering the base particle. The toner includes a tetrahydrofuran (THF)-insoluble component having a glass transition temperature determined from a DSC curve when heated for the second time of from ?50° C. to 10° C. and an average circularity not greater than 0.98, and satisfies the following relation: Bt?0.025×Ct?1.80 wherein Bt represents a BET specific surface area [m2/g]; and Ct represents a coverage [%] of the external additive covering the base particle.

Abstract: A toner includes a base particle comprising a crystalline polyester resin; and an external additive which is a group of silica particles having a number-average particle diameter of from 0.01 ?m to 0.11 ?m on the surface of the toner. A number ratio of the silica particles having a circularity not less than 0.8 is 20% or more in the total number of the silica particles.

Abstract: It is constituted such that a sterile work can be applied by a worker 29 to cells or the like through a glove 28 provided in an isolator 15. A headset 31 for work outputting a work procedure of the sterile work in voice is prepared for the worker, and an input device 39 for check is prepared for a checker 36. A management device 12 outputs the work procedure of the sterile work this time in voice to the headset for work. When the fact that the worker has normally performed the sterile work this time is checked by the checker, and when the fact is input from the input device for check to the management device, the management device performs the subsequent work procedure. Since the sterile work by the worker 29 can be monitored by the checker 36, a wrong work can be prevented from being performed.

Abstract: A device 2 for producing a three-dimensional structural body has an accommodating plate 3 in which an accommodating recess portion 3a for accommodating a cell mass 1 is formed, a support body 4 provided with a plurality of needle-shaped bodies 6 penetrating the cell mass, a suction nozzle 19 for adsorbing/holding the cell mass, and structure 20 for moving the suction nozzle.

Abstract: Provided is a pharmaceutical composition containing, as an active ingredient thereof, a substituted biaryl compound represented by general formula (I), wherein, R1, W, R2 and Z are as defined in the claims and description, or a pharmacologically acceptable salt thereof. The pharmaceutical composition of the present invention is useful as a therapeutic drug and/or prophylactic drug for chronic obstructive pulmonary disease due to having an excellent anti-inflammatory effect.

Abstract: The present invention provides a substituted biaryl compound of general formula (I): wherein, R1, W, R2, and Z are as defined in the claims and the description, or a pharmacologically acceptable salt thereof. The compound according to the present invention has an excellent inhibition effect of pulmonary fibroblast proliferation, and is therefore useful as a therapeutic agent and/or a prophylactic agent for interstitial pneumonia and pulmonary fibrosis.

Abstract: An image forming method is provided. The method includes the steps of forming an electrostatic latent image on a photoconductor; developing the electrostatic latent image into a toner image with a toner; transferring the toner image onto a recording medium having a smoothness of 20 s or less; and fixing the toner image on the recording medium. The toner exhibits an adhesion force of 100 gf or more, where the adhesion force is the maximum value of a pull force between a layer of the toner and standard paper determined by a tacking test with a probe temperature of 140° C.

Abstract: The present invention provides a substituted pyridine compound or a pharmacologically acceptable salt thereof which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a compound represented by a general formula (I), wherein R1 is H, optionally substituted alkyl, OH, optionally substituted alkoxy, alkylsulfonyl, optionally substituted amino, carboxy, optionally substituted carbonyl, CN, halogeno, optionally substituted phenyl, optionally substituted aromatic heterocyclyl, optionally substituted saturated heterocyclyl, optionally substituted saturated heterocyclyloxy or optionally substituted saturated heterocyclylcarbonyl, etc., and the like.

Abstract: An electric vehicle motor control device controls the transmission of power from an electric motor to driving wheels via an automatic transmission. The electric vehicle motor control device includes a vehicle speed detecting device that detects a vehicle speed of the electric vehicle and a controller. The controller includes a required driving power calculating section that calculates a required driving power of the electric vehicle, and a target motor rotational speed calculating section that calculates a target motor rotational speed. The target motor rotational speed is calculated so that an efficiency of a product of a power consumption rate of the electric motor and a transmission efficiency of the automatic transmission will become a prescribed target efficiency, based on the vehicle speed and the required driving power. The controller controls the electric motor based on the target motor rotational speed.

Abstract: A harvested sample preparation system includes an operation isolator 3 in which aseptic manipulation is executed, a harvested sample preparation personal box 4 which can be connected with the operation isolator 3 and a storage 5 that stores a plurality of harvested sample preparation personal boxes 4. The harvested sample preparation personal box 4 includes a first housing chamber 4Aa and a second housing chamber 4Ab, and a fluid appropriate for cell culturing is supplied to the first housing chamber 4Aa from a fluid supply pipe 16 included by the storage 5 while cooling fluid is supplied to the second housing chamber 4Ab from a cooling fluid supply pipe 18. The harvested sample preparation system that prevents mix-up and cross-contamination with a simple configuration can be provided.

Abstract: An electric vehicle motor control device controls the transmission of power from an electric motor to driving wheels via an automatic transmission. The electric vehicle motor control device includes a vehicle speed detecting device that detects a vehicle speed of the electric vehicle and a controller. The controller includes a required driving power calculating section that calculates a required driving power of the electric vehicle, and a target motor rotational speed calculating section that calculates a target motor rotational speed. The target motor rotational speed is calculated so that an efficiency of a product of a power consumption rate of the electric motor and a transmission efficiency of the automatic transmission will become a prescribed target efficiency, based on the vehicle speed and the required driving power. The controller controls the electric motor based on the target motor rotational speed.

Abstract: Provided is a method for manufacturing a semiconductor device which includes, on a wafer which has a notch, a plurality of transistors parallel with and perpendicular to a notch direction extending between the center of the wafer and the notch, the method including: preparing the wafer having the front surface which has Off angle of at least 2 degrees and at most 2.8 degrees from plane in a direction in which Twist angle relative to the notch direction is at least 12.5 degrees and at most 32.5 degrees; and doping impurities into the front surface of the wafer in a direction perpendicular to the front surface.

Abstract: The present invention provides a substituted pyridine compound or a pharmacologically acceptable salt thereof which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a compound represented by a general formula (I), wherein R1 is H, optionally substituted alkyl, OH, optionally substituted alkoxy, alkylsulfonyl, optionally substituted amino, carboxy, optionally substituted carbonyl, CN, halogeno, optionally substituted phenyl, optionally substituted aromatic heterocyclyl, optionally substituted saturated heterocyclyl, optionally substituted saturated heterocyclyloxy or optionally substituted saturated heterocyclylcarbonyl, etc., and the like.